Navigation Links
Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
Date:5/29/2012

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The dose escalation trial is expected to enroll up to 24 patients in up to five cohorts with final safety and pharmacokinetic data expected in the first half of 2013.

"We are very pleased to see the excitement surrounding our initial clinical trial of ME-344, with the first cohort of patients now well underway just a month after our Investigational New Drug application was approved by the FDA," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "ME-344 is a novel compound that showed compelling anti-tumor activity in pre-clinical studies. Now we look forward to gathering valuable clinical data in the months ahead, all of which will help to optimize the design of our Phase II efficacy studies."

The Phase I clinical trial is evaluating the safety and tolerability of intravenous ME-344 in escalating dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg. In addition, the trial is designed to characterize the pharmacokinetic profile of ME-344 and describe any preliminary clinical anti-tumor activity observed. Patients in the trial are administered intravenous infusions of ME-344 once weekly for three weeks and, after safety assessment, may continue weekly dosing if a clinical benefit is determined.

The open-label trial is being conducted in collaboration with the Sarah Cannon Research Institute at three sites: Florida Cancer Specialists in Sarasota, University of Oklahoma in Oklahoma City and Tennessee Oncology in Nashville. Additional information
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
3. Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
4. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
5. Marshall Edwards Announces Rights Offering to Stockholders
6. Marshall Edwards Adds $2 Million in Private Placement
7. Marshall Edwards Announces $2 Million Private Placement
8. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
9. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Calif. , July 31, 2014  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Access Conference, New York, NY Wednesday, ... Baird Health Care Conference, New York, NY ... Time , Accessing Live Webcasts To access the ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... 31, 2014 Dr. Stewart Shofner ... the first surgeons in the United States to successfully treat ... the smallest medical device ever approved by the FDA. ... recognize the benefits of using a procedure known as Selective ... Shofner and his colleagues now recognize that this procedure is ...
(Date:7/31/2014)... Las Vegas, NV (PRWEB) July 31, 2014 ... marketing expert Adam Short that is designed to provide a ... has caught the attention of Shane Michaels, prompting an investigative ... here . , “What really speaks volumes about the success ... the tactics and strategies included in it have stayed effective ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure verification ... will be able to verify their patients before the ... guarantees their authenticity. This will help prospective patients ... information that has been verified to come from a ... Town to filter out fake patients who leave fraudulent ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:United Theological Seminary to Open 144th Year 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... RICHMOND, Va., April 29 The principal U.S. investigator,for ... for,malpractice in his use of the device by a ... No. 07-206, Circuit Court, City of Richmond, Va., ... H.,Mathews, M.D., and Midatlantic Spine Specialists, P.C. Dr. Mathews ...
... 1950 had agreement on standard outcomes, review finds , , ... the appropriate measurements for assessing drug clinical trials that ... 9,000 pediatric clinical trials conducted since 1950. , They ... none have involved children in the process to select ...
... PITTSBURGH, April 29 Mylan Inc. (NYSE: MYL ... approval,from the U.S. Food and Drug Administration (FDA) for ... mg, 2 mg and 4 mg., Trandolapril Tablets ... and generic versions of this product had total U.S.,sales ...
... A New LTCI Presentation System Designed for Today,s ... LLC, the leader in,providing long-term care insurance sales, ... announced the release of,simplifyingLTC, a LTCI presentation system ... presentation system communicates the risk of long-term care ...
... More than 50,000 doctors,have given 20 million free ... to Reach Out and Read. Partnering with doctors ... to their parents at check-ups, Reach,Out and Read ... toddlers,and preschoolers. The children,s literacy program recently reached ...
... Growth of 27-29 Percent over ... 2007 First-Quarter Year-Over-Year Highlights (adjusted for January 2008 ... two-for-one stock split): - GAAP ... from $0.52, excluding $0.05 in amortization of intangible assets ...
Cached Medicine News:Health News:Virginia Judge Rules Medical Device Pioneer Committed Malpractice 2Health News:Measurements Poor for Assessing Clinical Trials With Children 2Health News:SellingLTC.com Develops simplifyingLTC 2Health News:20 Million Kids' Books Distributed, 25% of U.S. Children in Poverty Getting Books, 50,000 Doctors Trained: Three Key Milestones for Reach Out and Read 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 3Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 4Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 5Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 6Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 7Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 8Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 9Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 10Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 11Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 12Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 13Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 14Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 15Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 16Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 17Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 18Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 19Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 20Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 21Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 22Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 23Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 24Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 25
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... musculofascial tract, renal capsule, and parenchyma during ... the catheter shaft. Radiopaque markers are placed ... the balloon. The radiopaque dilator/sheath assembly is ... coaxial placement of the sheath. Supplied sterile ...
... Therapy for Urinary Control offers a ... and the symptoms of overactive bladder, ... symptoms of urgency-frequency alone or in ... or could not tolerate more conservative ...
... Receiving timely, high-quality and accurate,ECG ... care. The,Quinton Eclipse Premier allows ... test results,and make a diagnosis ... sharing capabilities.,Workload is further streamlined ...
Medicine Products: